Citi upgrades CV Therapeutics (Nasdaq: CVTX) from Sell to Hold. Price target increased from $9 to $11.

Citi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE